Dana-Farber’s Breast Oncology Center shared a post on X:
“Here’s the most recent Breast Cancer Research Digest – a summary of last week’s publications from select high-impact journals (February 18th-23rd, 2025).”
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
Authors: Herve Bonnefoi, et al.

Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.
Authors: Hee Kyung Ahn, et al.

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).
Authors: Jeffrey R Marks, et al.

Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.
Authors: Natasha B Hunter, et al.

Ultrasound-based quantitative microvasculature imaging for early prediction of response to neoadjuvant chemotherapy in patients with breast cancer.
Authors: Soroosh Sabeti, et al.

Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.
Authors: Zofia M Komar, et al.

CHEK2-related breast cancer: real-world challenges.
Authors: Luiza N. Weis, et al.

Racial and Ethnic Differences in Breast Inflammation and Its Association with Lymphedema Risk After Axillary Lymph Node Dissection.
Authors: Arielle Roberts, et al.

Real-World Assessment of Locoregional Management of the Axilla in Node-Positive Breast Cancer After Neoadjuvant Chemotherapy.
Authors: Katherine Fleshner, et al.

Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.
Authors: Reiner Hoppe, et al.

Integrating the environmental and genetic architectures of aging and mortality.
Authors: M. Austin Argentieri, et al.

Interaction between APOE E4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study.
Authors: Mylène Duivon, et al.

Temporal evolution of breast cancer brain metastases treatments and outcomes.
Authors: Michelle Bottosso, et al.

A matched case-control study of the relationship between radiation dose to the internal mammary lymph nodes and clinical outcomes in patients with and without internal mammary lymph node relapses.
Authors: Alan Nichol, et al.

The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype.
Authors: Polina Turova, et al.

Neighborhood disinvestment predicts shorter cancer survival time among Black women diagnosed with invasive breast cancer.
Authors: Jesse J Plascak, et al.

Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay.
Authors: Mitchell J. Elliott, et al.

Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer.
Authors: Nina Tamirisa, et al.

Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer.
Authors: Xue Yang, et al.
